SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Fang, C.-C.
Right arrow Articles by Wang, S.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, C.-C.
Right arrow Articles by Wang, S.-P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience

Ching-Chang Fang, MD

Cardiovascular Center, Tainan Municipal Hospital, Taiwan

Yeun Tarl Fresner Ng Jao, MD, FASA

Cardiovascular Center, Tainan Municipal Hospital, Taiwan, pogibomb{at}hotmail.com

Yi-Chen, MD

Cardiovascular Center, Tainan Municipal Hospital, Taiwan

Ching-Lung Yu, MD

Cardiovascular Center, Tainan Municipal Hospital, Taiwan

Chi-Liang Chen, MD

Cardiovascular Center, Tainan Municipal Hospital, Taiwan

Shih-Pu Wang, MD

Cardiovascular Center, Tainan Municipal Hospital, Taiwan

A beneficial effect of thiazolidinediones includes the reduction of intermediate markers, suggesting a potential for reducing atherosclerosis and restenosis. The objective of this study was to determine if rosiglitazone (RSG) reduced the odds of restenosis and if RSG improved the odds of clinical outcomes after percutaneous coronary intervention (PCI) in type 2 diabetes mellitus (DM) patients. A total of 609 patients with 734 lesions were selected from the period between January 1, 2001 and January 31, 2004. These patients were divided into 2 groups: a "control" group representing patients seen between January 1, 2001 and September 2002 when RSG was not available in our hospital and a "RSG treatment" group representing patients seen between September 2002 and January 31, 2004 when RSG was available in our hospital. Thus, 213 patients with 253 lesions (1.19 L/P) were placed in the RSG group and 396 patients with 481 lesions (1.21 L/P) were placed in the control group. Subgroup analysis based on the PCI received had 88 patients in the RSG arm receiving balloon angioplasty and 125 patients receiving coronary stenting; the control group had 187 and 209 patients, respectively, in the subgroups. Primary endpoint was angiographic restenosis at 6 months, and secondary endpoints were death, myocardial infarction, and target lesion revascularization. More patients in the control group were insulin-requiring, had poorer left ventricular function, but had a larger preprocedural minimal lumen diameter (pre-MLD). At 6 months, restenosis and reocclusion rates were lower in the RSG group (P = .014 and P = .006, respectively). Twenty-nine patients died in the control group versus 1 in the RSG group (P ≤ .001). RSG (P = .019), stenting (P = .005), preprocedural reference vessel diameter (P = .017), metformin (P = .022), pre-MLD (P < .001), hyperlipidemia (P = .016), and combined RSG and metformin (P = .020) were predictors of restenosis, while RSG (P = .016) and metformin (P = .029) were predictors of survival. In conclusion, RSG was found safe and well tolerated and was associated with reduced odds of restenosis, reocclusion, and mortality rates in type 2 DM patients independent of glycemic control and PCI performed.

References

  • Kip KE, Faxon DP, Detre KM, et al: Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 94:1818-25, 1996.[Abstract/Free Full Text]
  • Levine GN, Jacobs AK, Keeler GP, et al: Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-1). Am J Cardiol 79:748-55, 1997.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Abizaid A., Kornowski R., Mintz GS, et al: The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32:584-589, 1998.[Abstract/Free Full Text]
  • Elezi S., Kastrati A., Pache J., et al: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32:1866-1873, 1998.[Abstract/Free Full Text]
  • Law RE, Goetze S., Xi XP, et al: Expression and function of PPAR {gamma} in rat and human vascular smooth muscle cells. Circulation 101:1311-1318, 2000.[Abstract/Free Full Text]
  • Marx N., Imhof A., Froehlich J., et al: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107:1954-1957, 2003.[Abstract/Free Full Text]
  • Sidhu JS, Cowan D., Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42:1757-1763, 2003.[Abstract/Free Full Text]
  • Haffner SM, Greenberg AS, Weston WM, et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002.[Abstract/Free Full Text]
  • Sidhu JS, Cowan D., Kaski JC: Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 94:151-156, 2004.[Web of Science][Medline] [Order article via Infotrieve]
  • Wang CH, Ciliberti N., Li SH, et al: Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109:1392-400, 2004.[Abstract/Free Full Text]
  • Fukunaga Y., Itoh H., Doi K., et al: Thiazolidinediones, peroxisome proliferator-activated receptor {gamma} agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 158:113-119, 2001.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Varo N., Vicent D., Libby P., et al: Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107:2664-2669, 2003.[Abstract/Free Full Text]
  • Choi D., Kim SK, Choi SH, et al: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27:2654-2660, 2004.[Abstract/Free Full Text]
  • Takagi T., Yamamuro A., Tamita K., et al: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89:318-22, 2002.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Takagi T., Akasaka T., Yamamuro A., et al: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 36:1529-1535, 2000.[Abstract/Free Full Text]
  • Takagi T., Yamamuro A., Tamita K., et al: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146:E5, 2003.[CrossRef][Medline] [Order article via Infotrieve]
  • Osman A., Otero J., Brizolara A., et al: Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 147:E23, 2004.[CrossRef][Medline] [Order article via Infotrieve]
  • Marx N., Froehlich J., Siam L., et al: Antidiabetic PPAR gamma-activator rosiglitazone reduced MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Atheroscler Thromb Vasc Biol 23:283-288, 2003.[Abstract/Free Full Text]
  • Haffner SM: Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92:18J-26J, 2003.[Web of Science][Medline] [Order article via Infotrieve]
  • Marx N., Wohrle J., Nusser T., et al: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112:2792-2798, 2005.[Abstract/Free Full Text]
  • Sidhu JS, Kaposzta Z., Markus HS, et al: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Atheroscler Thromb Vasc Biol 24:930-934, 2004.[Abstract/Free Full Text]
  • Mak KH, Faxon DP: Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 24:1087-1103, 2003.[Abstract/Free Full Text]
  • Wang G., Wei J., Guan Y., et al: Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54:590-597, 2005.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Van Belle E, Ketelers R., Bauters C., et al: Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 103:1218-1224, 2001.[Abstract/Free Full Text]
  • Norhammar A., Malmberg K., Diderholm E., et al: Diabetes mellitus: the major risk factor of unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 43:585-591, 2004.[Abstract/Free Full Text]
  • Mathew V., Frye RL, Lennon R., et al: Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. Am J Cardiol 93:399-403, 2004.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • BARI Investigators: Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 96:1761-1769, 1997.[Abstract/Free Full Text]
  • Abizaid A., Costa MA, Centemero M., et al: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the arterial revascularization therapy study (ARTS) trial. Circulation 104:533-538, 2001.[Abstract/Free Full Text]
  • BARI Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335:217-225, 1996.[Abstract/Free Full Text]
  • King SB Iii, Lembo NJ, Weintraub WS, et al: A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory angioplasty versus surgery trial (EAST). N Engl J Med 331:1044-1050, 1994.[Abstract/Free Full Text]
  • Finn AV, Palacios IF, Kastrati A., Gold HK: Drug-eluting stents for diabetes mellitus: a rush to judgement? J Am Coll Cardiol 45:479-483, 2005.[Abstract/Free Full Text]
  • Kao J., Tobis J., McClelland RL, et al: Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 93:1347-1350, 2004.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Khan MA, St Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-11, 2002.[Abstract/Free Full Text]
  • Pache J., Kastrati A., Mehilli J., et al: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41:1283-1288, 2003.[Abstract/Free Full Text]

Angiology, Vol. 58, No. 5, 523-534 (2007)
DOI: 10.1177/0003319707303587
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Fang, C.-C.
Right arrow Articles by Wang, S.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, C.-C.
Right arrow Articles by Wang, S.-P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement